Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 01, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	BIOTIME INC
Entity Central Index Key	0000876343
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		126,865,646
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands

Sep. 30, 2017

Dec. 31, 2016

CURRENT ASSETS

Cash and cash equivalents

$ 16,662

$ 22,088

Available for sale securities

1,511

627

Grants and other accounts receivable

1,420

646

Receivable from affiliates, net (Note 9)

2,278

511

Prepaid expenses and other current assets

1,354

1,777

Total current assets

23,225

25,649

Property, plant and equipment, net

5,423

^[1]

5,529

Deposits and other long-term assets

1,005

1,149

Intangible assets, net

7,482

^[1]

10,206

TOTAL ASSETS

221,867

142,572

CURRENT LIABILITIES

Accounts payable and accrued liabilities

5,360

^[1]

7,144

Capital lease liability, current portion

202

Promissory notes, current portion

126

833

Deferred revenues, current portion

513

572

Total current liabilities

6,012

8,850

LONG-TERM LIABILITIES

Deferred revenues, net of current portion

308

Deferred rent liabilities, net of current portion

Lease liability

1,257

1,386

Capital lease liability, net of current and other liabilities

310

1,032

Promissory notes, net of current portion

120

Deferred tax liability

4,845

Other long-term liabilities

554

TOTAL LIABILITIES

12,880

12,064

Commitments and contingencies (Note 13)

SHAREHOLDERS' EQUITY

Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of September 30, 2017 and December 31, 2016

Common shares, no par value, 150,000 shares authorized; 115,804 shares issued and outstanding as of September 30, 2017, and 103,396 shares issued and 102,776 shares outstanding as of December 31, 2016

342,508

317,878

Accumulated other comprehensive income (loss)

141

(738)

Accumulated deficit

(144,363)

(196,321)

Treasury stock at cost: no shares as of September 30, 2017; 620 shares as of December 31, 2016

(2,891)

BioTime, Inc. shareholders' equity

198,286

117,928

Noncontrolling interest

10,701

12,580

Total shareholders' equity

208,987

130,508

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

221,867

142,572

OncoCyte Corporation [Member]

CURRENT ASSETS

Equity method investment, at fair value

110,790

Asterias Biotherapeutics, Inc. [Member]

CURRENT ASSETS

Equity method investment, at fair value

$ 73,942

$ 100,039

[1]	Reflects the effect of the OncoCyte Deconsolidation.

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
SHAREHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, authorized (in shares)	2,000,000	2,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	115,804,040	103,396,245
Common stock, outstanding (in shares)	115,804,040	102,776,539
Treasury stock (in shares)	0	619,706

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
REVENUES:
Grant income	$ 1,225	$ 1,109	$ 1,236	$ 3,346
Royalties from product sales and license fees	86	177	277	463
Subscription and advertisement revenues	376	69	940	700
Sale of research products	1	144	6	331
Total revenues	1,688	1,499	2,459	4,840
Cost of sales	(52)	(58)	(114)	(378)
Gross Profit	1,636	1,441	2,345	4,462
OPERATING EXPENSES:
Research and development	(6,562)	(6,422)	(19,327)	(29,093)
General and administrative	(4,587)	(4,574)	(14,111)	(23,083)
Total operating expenses	(11,149)	(10,996)	(33,438)	(52,176)
Gain on sale of assets	0	0	1,754	0
Loss from operations	(9,513)	(9,555)	(29,339)	(47,714)
OTHER INCOME/(EXPENSES):
Interest expense, net	(10)	(167)	(729)	(513)
Loss on extinguishment of related party convertible debt	(2,799)	0	(2,799)	0
Other income (expenses), net	(143)	(173)	1,202	197
Total other income, net	28,271	38,820	82,894	74,075
INCOME BEFORE INCOME TAXES	18,758	29,265	53,555	26,361
Deferred income tax expense	(4,772)	0	(4,772)	0
NET INCOME	13,986	29,265	48,783	26,361
Net loss attributable to noncontrolling interests	335	1,934	3,175	12,286
NET INCOME ATTRIBUTABLE TO BIOTIME, INC.	$ 14,321	$ 31,199	$ 51,958	$ 38,647
NET INCOME PER COMMON SHARE ATTRIBUTABLE TO BIOTIME, INC.:
BASIC (in dollars per share)	$ 0.12	$ 0.30	$ 0.47	$ 0.40
DILUTED (in dollars per share)	$ 0.12	$ 0.30	$ 0.47	$ 0.39
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	115,288	102,711	110,989	95,484
DILUTED (in shares)	115,298	103,613	111,124	99,073
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
Gain (loss) on equity method investment at fair value	$ 34,485	$ 0	$ 39,620	$ 0
Gain on deconsolidation	0	0	71,697	0
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
Gain (loss) on equity method investment at fair value	(3,262)	40,015	(26,097)	26,532
Gain on deconsolidation	0	0	0	49,048
Ascendance Biotechnology, Inc. [Member]
OTHER INCOME/(EXPENSES):
BioTime's share of losses in equity method investment	$ 0	$ (855)	$ 0	$ (1,189)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) [Abstract]
NET INCOME	$ 13,986	$ 29,265	$ 48,783	$ 26,361
Other comprehensive income (loss), net of tax:
Change in foreign currency translation	(349)	(307)	56	(334)
Available for sale investments:
Unrealized gain (loss) on available-for-sale securities, net of taxes	219	121	822	(119)
COMPREHENSIVE INCOME	13,856	29,079	49,661	25,908
Less: Comprehensive loss attributable to noncontrolling interest	335	1,934	3,175	12,286
COMPREHENSIVE INCOME ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ 14,191	$ 31,013	$ 52,836	$ 38,194

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income attributable to BioTime, Inc.	$ 51,958	$ 38,647
Net loss allocable to noncontrolling interests	(3,175)	(12,286)
Adjustments to reconcile net income attributable to BioTime, Inc. to net cash used in operating activities:
Deferred income tax expense	4,772	0
Depreciation expense, including amortization of leasehold improvements	670	996
Amortization of intangible assets	1,766	2,935
Amortization of deferred license fees	(166)	1,191
Stock-based compensation	2,903	6,303
Subsidiary shareholder expense for subsidiary warrants	531	3,125
Amortization of discount on related party convertible debt	640	264
Foreign currency remeasurement (gain) or loss and other	(1,511)	802
Gain on sale of assets	(1,754)	0
Loss on extinguishment of related party convertible debt	2,799	0
Changes in operating assets and liabilities:
Grants and other accounts receivable, net	(905)	(955)
Deferred revenue and other liabilities	(279)	509
Receivables from affiliates, net of payables	760	0
Prepaid expenses and other current assets	93	(1,013)
Accounts payable and accrued liabilities	1,276	399
Net cash used in operating activities	(24,842)	(33,474)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment and other assets	(930)	(1,860)
Payments on construction in progress	0	(278)
Proceeds from sales of assets and other	186	34
Cash used in investing activities	(9,642)	(10,480)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares	20,125	20,125
Fees paid on sale of common shares	(1,623)	(1,515)
Proceeds from sale of common shares of subsidiary	9,968	0
Proceeds from exercises of stock options	29	2,015
Reimbursement from landlord on construction in progress	198	451
Shares retired to pay for employees' taxes	(38)	0
Repayment of capital lease obligation	(31)	(104)
Proceeds from sale of common shares and warrants of subsidiary	0	10,721
Fees paid on sale of common shares and warrants of subsidiary	0	(904)
Proceeds from issuance of related party convertible debt	384	1,150
Net cash provided by financing activities	29,012	31,939
Effect of exchange rate changes on cash and cash equivalents	46	237
NET DECREASE IN CASH AND CASH EQUIVALENTS	(5,426)	(11,778)
CASH AND CASH EQUIVALENTS:
At beginning of the period	22,088	42,229
At end of the period	16,662	30,451
Asterias Biotherapeutics [Member]
Adjustments to reconcile net income attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation	0	(49,048)
Unrealized (gain) loss on equity method investment in Asterias at fair value	26,097	(26,532)
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents	0	(8,376)
Ascendance Biotechnology, Inc. [Member]
Adjustments to reconcile net income attributable to BioTime, Inc. to net cash used in operating activities:
BioTime's share of losses in equity method investment	0	1,189
OncoCyte Corporation [Member]
Adjustments to reconcile net income attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation	(71,697)	0
Unrealized (gain) loss on equity method investment in Asterias at fair value	(39,620)	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents	$ (8,898)	$ 0

Organization and Business Overview

9 Months Ended

Sep. 30, 2017

Organization and Business Overview [Abstract]

Organization and Business Overview

1.	Organization and Business Overview

General – BioTime is a late-stage, clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are targeting three primary sectors: aesthetics, ophthalmology and cell/drug delivery. BioTime's clinical programs are based on two platform technologies: pluripotent cells that are capable of becoming any of the cell types in the human body, and a proprietary three dimensional cell and drug delivery matrix technology. The foundation of BioTime's cell delivery platform is its HyStem^® 3-D cell and drug delivery matrix technology.

BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. ("Asterias") and OncoCyte Corporation ("OncoCyte"), which BioTime founded and, until recently, were majority-owned and consolidated subsidiaries. Asterias (NYSE American: AST) is presently focused on advancing three clinical-stage programs that have the potential to address areas of very high unmet medical needs in the fields of neurology (spinal cord injury) and oncology (Acute Myeloid Leukemia and lung cancer). OncoCyte (NYSE American: OCX) is developing confirmatory diagnostic tests for lung cancer, breast cancer, and bladder cancer utilizing novel liquid biopsy technology.

Beginning on February 17, 2017, BioTime deconsolidated OncoCyte's financial statements and results of operations from BioTime (the "OncoCyte Deconsolidation") (see Notes 3 and 4).

Beginning on May 13, 2016, BioTime also deconsolidated Asterias’ financial statements and results of operations from BioTime (the "Asterias Deconsolidation") (see Notes 3 and 5).

BioTime also seeks to leverage its substantial intellectual property portfolio by advancing early-stage programs. On January 6, 2017, BioTime formed AgeX Therapeutics, Inc. ("AgeX") to continue development of early-stage programs. AgeX will focus on the development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders. Its initial programs will focus on utilizing brown adipose tissue ("brown fat") targeting diabetes and obesity, regenerative vascular progenitors for cardiovascular repair and our PureStem^® technology with new discoveries in telomerase manipulation to create induced tissue regeneration ("iTR"). AgeX may pursue other early-stage programs. As further discussed in Note 10, on August 17, 2017, AgeX completed an asset acquisition and stock sale pursuant to which it received certain assets from BioTime for use in its research and development programs and raised $10.0 million in cash to finance its operations. As of August 17, 2017, BioTime owned approximately 85% of the issued and outstanding shares of AgeX common stock (see Notes 2 and 10).

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies

2.	Basis of Presentation, Liquidity and Summary of Significant Accounting Policies

The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of December 31, 2016 was derived from the audited consolidated financial statements at that date, but does not include all the information and footnotes required by GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in BioTime's Annual Report on Form 10-K for the year ended December 31, 2016.

The accompanying interim condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of BioTime's financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

Principles of consolidation – BioTime's consolidated financial statements present the operating results of all of its wholly-owned and majority-owned subsidiaries that it consolidates as required under GAAP. All material intercompany accounts and transactions have been eliminated in consolidation. BioTime consolidated ReCyte Therapeutics, Inc. ("ReCyte"), OrthoCyte Corporation ("OrthoCyte"), ES Cell International, Pte Ltd ("ESI"), Cell Cure Neurosciences, Ltd ("Cell Cure"), BioTime Asia, Limited ("BioTime Asia"), LifeMap Sciences, Inc. ("LifeMap Sciences") LifeMap Sciences, Ltd., LifeMap Solutions, Inc. ("LifeMap Solutions") and AgeX Therapeutics, Inc. ("AgeX"), as BioTime has the ability to control their operating and financial decisions and policies through its ownership or representation on the board of directors, and the noncontrolling interest is reflected as a separate element of shareholders' equity on BioTime's condensed consolidated balance sheets.

Although beginning on February 17, 2017 and May 13, 2016, respectively, OncoCyte and Asterias financial statements and results are no longer a part of BioTime's consolidated financial statements and results, the market value of OncoCyte and Asterias common stock, as of those respective dates, held by BioTime is reflected on BioTime's consolidated balance sheets and the subsequent changes in the market value of those shares will be reflected in BioTime's consolidated balance sheets and consolidated statements of operations, allowing BioTime shareholders to evaluate the value of the respective OncoCyte and Asterias' portion of BioTime's business.

As of December 31, 2016, OncoCyte's assets, liabilities and net assets are included in the consolidated balance sheet of BioTime, after intercompany eliminations.

OncoCyte's results of operations, comprehensive income or loss, and cash flows for the period from January 1, 2017 through February 16, 2017 are included in BioTime's condensed consolidated statements of operations, condensed consolidated statements of comprehensive income or loss and condensed consolidated statements of cash flows for the nine months ended September 30, 2017, after intercompany eliminations (see Notes 3 and 4). OncoCyte's results are not included in BioTime's unaudited condensed consolidated statements of operations and condensed consolidated statements of comprehensive income or loss for the three months ended September 30, 2017.

OncoCyte's results of operations, comprehensive income or loss and cash flows for the three and nine months ended September 30, 2016 are included in BioTime's condensed consolidated statements of operations, condensed consolidated statements of comprehensive income or loss and condensed consolidated statements of cash flows, after intercompany eliminations (see Notes 3 and 4).

Asterias' results of operations, comprehensive income or loss, and cash flows for the period from January 1, 2016 through May 12, 2016 are included in BioTime's condensed consolidated statements of operations, condensed consolidated statements of comprehensive income or loss and condensed consolidated statements of cash flows for the nine months ended September 30, 2016. Asterias' results are not included in BioTime's condensed consolidated statements of operations and condensed consolidated statements of comprehensive income or loss for the three months ended September 30, 2016.

Liquidity – Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, payments from research grants, royalties from product sales and sales of research products and services. At September 30, 2017, BioTime had an accumulated deficit of $144.4 million, working capital of $17.2 million and shareholders' equity of $209.0 million. BioTime has evaluated its projected cash flows and believes that its $18.2 million of cash, cash equivalents and available for sale securities as of September 30, 2017, and the net proceeds of approximately $26.7 million raised in an underwritten public offering on October 17, 2017 (see Note 14) provide sufficient cash, cash equivalents and liquidity to carry out BioTime's current operations through at least twelve months from the issuance date of the condensed consolidated interim financial statements included herein. BioTime also holds shares of Asterias and OncoCyte common stock with a combined value of $184.7 million at September 30, 2017. Although BioTime has no present plans to liquidate its holdings of Asterias or OncoCyte shares, if BioTime needs near term working capital or liquidity to supplement its cash and cash equivalents for its operations, BioTime may sell some, or all, of its Asterias or OncoCyte shares, as necessary.

BioTime's projected cash flows are subject to various risks and uncertainties and the unavailability or inadequacy of financing to meet future capital needs could force BioTime to modify, curtail, delay, or suspend some or all aspects of its planned operations. For example, clinical trials of BioTime's OpRegen^®cell therapy treatment of age related macular degeneration will be funded in part with funds from grants and not from cash on hand. If the OpRegen^® program were to lose its grant funding or BioTime becomes unable to continue to provide working capital to fund the OpRegen^® clinical trial, BioTime may be required to delay, postpone, or cancel the clinical trial or limit the number of clinical trial sites, unless it is able to obtain adequate financing from another source that could be used for its clinical trial. BioTime's determination as to when it will seek new financing and the amount of financing that it will need will be based on BioTime's evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, and projection of future costs, revenues, and rates of expenditure. BioTime cannot assure that adequate financing will be available on favorable terms, if at all. Sales of additional equity securities by BioTime or its subsidiaries could result in the dilution of the interests of present shareholders.

On August 8, 2017, the Israel Innovation Authority (the "IIA") approved a grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2.0 million) for the development of OpRegen^®. As of September 30, 2017, BioTime recorded a $1.2 million grant receivable from the IIA related to this grant.

On September 18, 2017, BioTime was awarded a grant of up to $1.56 million from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). The SBIR grant provides funding to further develop BioTime’s innovative, next generation vision restoration program for advanced retinal diseases and injuries. The SBIR grant funds will be made available by NIH for payment to BioTime as allowable expenses are incurred by BioTime. As of September 30, 2017, no amounts were recorded in the consolidated financial statements.

As further discussed in Note 10, on August 17, 2017, AgeX completed an asset acquisition and stock sale pursuant to which it received certain assets from BioTime for use in its research and development programs and raised $10.0 million in cash primarily from new investors to finance its operations. However, BioTime cannot assure that adequate financing will be available to AgeX in the future to fund the AgeX programs.

Equity method accounting for Asterias and OncoCyte, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations in other income and expenses, net.

As further discussed in Notes 4 and 5, BioTime has elected to account for its Asterias and OncoCyte shares at fair value using the equity method of accounting because beginning on May 13, 2016 and February 17, 2017, the respective dates on which BioTime deconsolidated Asterias and OncoCyte, BioTime has not had control of Asterias and OncoCyte, as defined by GAAP since the applicable deconsolidation dates, but BioTime continues to exercise significant influence over Asterias and OncoCyte. Under the fair value method, the value of the shares of common stock BioTime holds in Asterias and OncoCyte is marked to market using the closing prices of Asterias and OncoCyte common stock on the NYSE American multiplied by the number of shares of Asterias and OncoCyte held by BioTime, with changes in the fair value of the Asterias and OncoCyte shares included in other income and expenses, net, in the condensed consolidated statements of operations. The Asterias and OncoCyte shares are considered level 1 assets as defined by ASC 820, Fair Value Measurements and Disclosures.

Foreign currency transaction gains and losses – For transactions denominated in other than the functional currency of BioTime or its subsidiaries, BioTime recognizes transaction gains and losses in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The majority of BioTime’s foreign currency transaction gains and losses are generated by Cell Cure’s intercompany debt due to BioTime (see Note 9), which are U.S. dollar-denominated, while Cell Cure’s functional currency is the Israeli New Shekel. Accordingly, foreign currency remeasurement gains and losses related to this debt are included in other income and expenses, net.

Basic and diluted net income (loss) per share attributable to common shareholders – Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by BioTime, if any, during the period. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under outstanding stock options and warrants, using the treasury-stock method, convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any.

The primary components of the weighted average number of potentially dilutive common shares used to compute diluted net income per common share for the three months ended September 30, 2017 were approximately 10,000 outstanding stock options and restricted stock units. The primary components of the weighted average number of potentially dilutive common shares used to compute diluted net income per common share for the nine months ended September 30, 2017 were approximately 109,000 shares of treasury stock (see Note 10), and approximately 26,000 outstanding stock options and restricted stock units. The primary components of weighted average shares of potentially dilutive common shares used to compute diluted net income per common share for the three months ended September 30, 2016 were approximately 620,000 shares of treasury stock (see Note 10), and approximately 282,000 restricted stock units and outstanding stock options. For the nine months ended September 30, 2016, potentially dilutive shares were approximately 3.4 million shares of treasury stock and approximately 154,000 restricted stock units and outstanding stock options (see Note 11).

The following common share equivalents were excluded from the computation of diluted net income per common share for the periods presented because including them would have been antidilutive (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Stock options		7,915		5,652		7,871		5,652
Warrants		9,395		9,395		9,395		9,395

Reclassifications – Gain on sale of assets of $1.8 million generated during the three and six months ended June 30, 2017 and included in other income and expenses, net, on the consolidated statements of operations has been reclassified to be included in loss from operations in the consolidated statements of operations for the nine months ended September 30, 2017 to properly reflect the nature of the gain. This reclassification had no impact on the net income or loss, no impact on consolidated cash flows and consolidated balance sheets for any period presented.

For the nine months ended September 30, 2016 BioTime regrouped certain amounts in the operating section of the condensed consolidated statements of cash flows to conform to the presentation for the nine months ended September 30, 2017.

Recently Issued Accounting Pronouncements – The recently issued accounting pronouncements discussed below should be read in conjunction with the other recently issued accounting pronouncements as applicable and disclosed in BioTime's Annual Report on Form 10-K for the year ended December 31, 2016, and Quarterly Report on Form 10-Q for the first and second quarters of 2017.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815), in two parts. Part I of this ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option, with changes in fair value of that instrument recognized in earnings of the entity. Part II is related to nonpublic entities and is not applicable to BioTime.

Under Part I of the new guidance in ASU 2017-11, when determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS.

The amendments in Part I of ASU 2017-11 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. Since BioTime currently has no financial instruments with down round features, BioTime does not expect any impact to its consolidated financial statements upon adoption.

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) – Scope of Modification Accounting, to clarify existing guidance and reduce diversity in practice about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 requires modification accounting to a share-based award unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award, as equity or liability instrument, is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. BioTime applies the three-step test to all modifications, if any, or as they occur, and if all the conditions are not met, applies modification accounting. BioTime believes the adoption of ASU 2017-09 will not have a material impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgments and estimates may be required in the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).

BioTime is currently evaluating the impact of this standard on its operations, consolidated financial statements and footnote disclosures and is finalizing the overall assessment of the impact of the standard to BioTime. Preliminarily, BioTime intends to apply the modified retrospective method of adoption on its adoption date of January 1, 2018, and it anticipates expanded disclosures on revenues in order to comply with the new standard.

Deconsolidation of OncoCyte and Asterias

9 Months Ended

Sep. 30, 2017

Deconsolidation of OncoCyte and Asterias [Abstract]

Deconsolidation of OncoCyte and Asterias

3.	Deconsolidation of OncoCyte and Asterias

On February 17, 2017, OncoCyte issued 625,000 shares of OncoCyte common stock to certain investors who exercised their OncoCyte warrants. The warrants had been issued as part of OncoCyte's financing that was completed on August 29, 2016. As a result of the issuance of the 625,000 shares of OncoCyte common stock, beginning on February 17, 2017, BioTime owned less than 50% of the OncoCyte outstanding common stock and experienced a loss of control of the OncoCyte subsidiary. Under GAAP, loss of control of a subsidiary is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability to elect a majority of the subsidiary's Board of Directors. BioTime determined that all of those loss of control factors were present with respect to OncoCyte on February 17, 2017. Accordingly, BioTime deconsolidated OncoCyte's financial statements and results of operations from BioTime, effective February 17, 2017, in accordance with ASC, 810-10-40-4(c), Consolidation, referred to as the "OncoCyte Deconsolidation".

Beginning on February 17, 2017, BioTime is accounting for its retained noncontrolling investment in OncoCyte under the equity method of accounting and has elected the fair value option under ASC 825-10, Financial Instruments (see Note 4).

In connection with the OncoCyte Deconsolidation and in accordance with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation of $71.7 million which is included in other income and expenses, net, in the condensed consolidated statements of operations (see Note 12) for the nine months ended September 30, 2017.

As previously reported, BioTime deconsolidated Asterias' financial statements and results of operations from BioTime effective May 13, 2016.

Equity Method Accounting for Common Stock of OncoCyte, at fair value

9 Months Ended

Sep. 30, 2017

Equity Method Accounting for Common Stock of OncoCyte, at fair value [Abstract]

Equity Method Accounting for Common Stock of OncoCyte, at fair value

4.	Equity Method Accounting for Common Stock of OncoCyte, at fair value

BioTime elected to account for its 14.7 million shares of OncoCyte common stock at fair value using the equity method of accounting beginning on February 17, 2017, the date of the OncoCyte Deconsolidation. The OncoCyte shares had a fair value of $110.8 million as of September 30, 2017 and a fair value of $71.2 million as of February 17, 2017, based on the closing prices of OncoCyte common stock on the NYSE American of $7.55 per share and $4.85 per share on those respective dates. For the three months ended September 30, 2017, BioTime recorded an unrealized gain of $34.5 million on the OncoCyte shares due to the increase in OncoCyte's stock price from June 30, 2017 to September 30, 2017 based on the closing prices of OncoCyte common stock on the NYSE American of $5.20 per share and $7.55 per share on those respective dates. For the nine months ended September 30, 2017, BioTime recorded an unrealized gain of $39.6 million on the OncoCyte shares due to the increase in OncoCyte's stock price from February 17, 2017 to September 30, 2017, based on the closing prices of OncoCyte common stock on the NYSE American of $4.85 per share and $7.55 per share on those respective dates.

The unaudited condensed results of operations for the three and nine months ended September 30, 2017 and 2016 and for the period January 1, 2017 to February 16, 2017 are summarized below (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,						For the Period January 1, 2017 to February 16, 2017
	2017			2016			2017			2016
Condensed Statements of Operations (unaudited) ⁽¹⁾:
Research and development expense	$	1,836		$	1,363		$	5,667		$	4,246		$	798
General and administrative expense		4,289			1,063			7,447			3,145			377
Sales and marketing expense		710			156			1,843			655			213
Loss from operations		(6,835	)		(2,582	)		(14,957	)		(8,046	)		(1,388	)
Net loss	$	(6,906	)	$	(2,595	)	$	(15,415	)	$	(8,065	)	$	(1,392	)

⁽¹⁾ The condensed unaudited statements of operations information included in the table above for the period January 1, 2017 through February 16, 2017, and for the three and nine months ended September 30, 2016, reflects OncoCyte results of operations included in BioTime's condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016, as applicable, respectively, after intercompany eliminations. The information for OncoCyte for the period from February 17, 2017 through September 30, 2017 is not included in BioTime's condensed consolidated statements of operations for the three and nine months ended September 30, 2017, due to the OncoCyte Deconsolidation on February 17, 2017.

Equity Method Accounting for Common Stock of Asterias, at fair value

9 Months Ended

Sep. 30, 2017

Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract]

Equity Method Accounting for Common Stock of Asterias, at fair value

5.	Equity Method Accounting for Common Stock of Asterias, at fair value

BioTime elected to account for its 21.7 million shares of Asterias common stock at fair value using the equity method of accounting beginning on May 13, 2016, the date of the Asterias Deconsolidation. The Asterias shares had a fair value of $73.9 million as of September 30, 2017 and a fair value of $100 million as of December 31, 2016, based on the closing prices of Asterias common stock on the NYSE American of $3.40 per share and $4.60 per share on those respective dates. For the three months ended September 30, 2017, BioTime recorded an unrealized loss of $3.3 million on the Asterias shares due to the decrease in Asterias' stock price from June 30, 2017 to September 30, 2017, based on the closing prices of Asterias common stock on the NYSE American of $3.55 per share and $3.40 per share on those respective dates. For the nine months ended September 30, 2017, BioTime recorded an unrealized loss of $26.1 million on the Asterias shares due to the decrease in Asterias' stock price from December 31, 2016 to September 30, 2017, based on the closing prices of Asterias common stock on the NYSE American of $4.60 per share and $3.40 per share on those respective dates.

The unaudited condensed results of operations for the three and nine months ended September 30, 2017 and 2016 and for the period from January 1, 2016 through May 12, 2016 are summarized below (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,						For the Period January 1, 2016 to May 12, 2016
	2017			2016			2017			2016
Condensed Statements of Operations (unaudited) ^(1):
Total revenue	$	1,688		$	2,076		$	4,014		$	5,202		$	2,354
Gross profit		1,607			2,017			3,863			5,084			2,301
Loss from operations		(7,063	)		(7,425	)		(24,703	)		(25,591	)		(13,944	)
Net loss	$	(6,809	)	$	(10,648	)	$	(21,824	)	$	(26,144	)	$	(13,113	)

⁽¹⁾ The condensed unaudited statement of operations information included in the table above reflects Asterias' results of operations for the three and nine months ended September 30, 2017 and 2016. The periods shown are provided for comparative purposes only, and the condensed results of operations of Asterias shown for the three and nine months ended September 30, 2017 were not included in BioTime's condensed consolidated statements of operations. The unaudited results of operations of Asterias for the period January 1, 2016 through May 12, 2016 only are included in the unaudited condensed consolidated results of BioTime for the nine months ended September 30, 2016 due to the Asterias Deconsolidation on May 13, 2016.

Property, plant and equipment, net

9 Months Ended

Sep. 30, 2017

Property, plant and equipment, net [Abstract]

Property, plant and equipment, net

6.	Property, plant and equipment, net

At September 30, 2017 and December 31, 2016, property, plant and equipment was comprised of the following (in thousands):

	September 30, 2017 (unaudited)⁽¹⁾			December 31, 2016
Equipment, furniture and fixtures	$	4,085		$	4,718
Leasehold improvements		4,207			3,791
Accumulated depreciation and amortization		(2,869	)		(2,980	)
Property, plant and equipment, net	$	5,423		$	5,529

⁽¹⁾ Reflects the effect of the OncoCyte Deconsolidation.

Depreciation expense, including amortization of leasehold improvements, amounted to $670,000 and $996,000 for the nine months ended September 30, 2017 and 2016, respectively.

Related Party Transactions

9 Months Ended

Sep. 30, 2017

Related Party Transactions

9.	Related Party Transactions

Related Party Convertible Debt

Cell Cure issued certain convertible promissory notes (the "Convertible Notes") to Cell Cure shareholders other than BioTime. The functional currency of Cell Cure is the Israeli New Shekel however the Convertible Notes are payable in United States dollars. Consequently, at each balance sheet date, Cell Cure remeasures the Convertible Notes issued to BioTime and other Cell Cure shareholders using the current exchange rate at that date pursuant to ASC 830, Foreign Currency Matters. These foreign currency remeasurement gains and losses are included in other income and expense, net. The Convertible Notes bear a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Notes, with accrued interest, were due and payable on various maturity dates in July 2017 and September 2017, and in February 2019 through August 2019. The outstanding principal balance of the Convertible Notes with accrued interest was convertible into Cell Cure ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Notes was required to be settled with Cell Cure ordinary shares and not with cash. The conversion feature of the Convertible Notes issued was not accounted for as an embedded derivative under the provisions of ASC 815, Derivatives and Hedging since it was not a freestanding financial instrument and the underlying Cell Cure ordinary shares are not readily convertible into cash. Accordingly, the Convertible Notes were accounted for under ASC 470-20, Debt with Conversion and Other Options (ASC 470-20). Under ASC 470-20, BioTime determined that a beneficial conversion feature ("BCF") was present on the issuance dates of the Convertible Notes. A conversion feature is beneficial if, on the issuance dates, the effective conversion price is less than the fair value of the issuer's capital stock. Since the effective conversion price of $20.00 per share is less than the estimated range of fair values from $28.00 per share to $40.00 per share of Cell Cure ordinary shares on the dates the Convertible Notes were issued, a beneficial conversion feature, equal to the intrinsic value ranging from $8 per share to $20 per share, was present. In accordance with ASC 470-20-30-8, if the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. The BCF was recorded as an addition to equity with a corresponding debt discount on the Convertible Notes' issuance date. This debt discount was amortized to interest expense using the effective interest method over the term of the debt, generally three years, representing an approximate effective annual interest rate between 11% and 23%. As of December 31, 2016, the carrying value of the Convertible Notes was $1,865,000, comprised of principal and accrued interest of $2,544,000, net of unamortized debt discount of $679,000.

On July 10, 2017, BioTime purchased all of the outstanding Cell Cure Convertible Notes and Cell Cure ordinary shares held by Hadasit Bio-Holdings Ltd. ("HBL"), a Cell Cure shareholder that owned 21.2% of the issued and outstanding Cell Cure ordinary shares (see Note 10) and substantially all of the Cell Cure Convertible Notes issued by Cell Cure to shareholders other than BioTime. BioTime issued 1,220,207 common shares valued at $3.8 million to purchase the Cell Cure ordinary shares and 2,776,662 common shares valued at $8.6 million to purchase the Cell Cure Convertible Notes held by HBL. The value of the BioTime common stock issued was determined based on the closing price of BioTime common shares on the NYSE American on July 10, 2017, or $3.09 per share.

The purchase of the Cell Cure Convertible Notes from HBL was accounted for as an extinguishment of a convertible debt with a beneficial conversion feature under ASC 470-50-40, Debt – Modifications and Extinguishments. This guidance requires an entity to recognize the difference between the reacquisition price and the net carrying value of the extinguished debt, including any unamortized discount relating to the BCF, as a gain or loss on extinguishment in the statement of operations. The entity must also calculate the intrinsic value, if any, of the conversion option of the debt and charge this amount to equity and allocate the remainder of the reacquisition price to the extinguishment of the debt and record a gain or loss on debt extinguishment by comparing the reacquisition price allocated to the debt with the net carrying value amount of the debt.

In connection with the purchase of all of the outstanding Cell Cure Convertible Notes from HBL and in accordance with ASC 470-50-40, BioTime recorded a charge to equity of $3.1 million representing the intrinsic value of the conversion option of the Cell Cure Convertible Notes, and a $2.8 million noncash loss on debt extinguishment included in other income and expenses, net, during the three and nine months ended September 30, 2017.

Shared Facilities and Service Agreements with Affiliates

The receivables from affiliates shown on the condensed consolidated balance sheet as of September 30, 2017 primarily represents amounts owed to BioTime from OncoCyte under a Shared Facilities and Service Agreement (the "Shared Facilities Agreement"). Under the terms of the Shared Facilities Agreement, BioTime allows OncoCyte to use BioTime's premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime also provides accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime also has provided OncoCyte with the services of laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises.

BioTime charges OncoCyte a "Use Fee" for services provided and usage of BioTime facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates to OncoCyte costs incurred, including costs for services of BioTime employees and use of equipment, insurance, leased space, professional services, software licenses, supplies and utilities. The allocation of costs depends on key cost drivers, including actual documented use, square footage of facilities used, time spent, costs incurred by BioTime for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime. BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime elected not to charge this markup from the inception of the Shared Facilities Agreement through December 31, 2015. For allocated costs incurred beginning on January 1, 2016, BioTime is charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services.

The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through September 30, 2017, BioTime has not charged OncoCyte any interest.

In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers to invoice OncoCyte directly.

The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement is otherwise terminated under another provision of the agreement.

As of September 30, 2017, BioTime has a $2.1 million receivable from OncoCyte included in receivable from affiliates, net, on account of Use Fees incurred by OncoCyte under the Shared Facilities Agreement. Since these amounts are due and payable within 30 days of being invoiced, the receivable is classified as a current asset. The remaining $0.3 million receivable from affiliate is due from Ascendance Biotechnology, Inc. ("Ascendance"), an equity method investee of BioTime, net of allowance for doubtful accounts, for similar shared services performed by BioTime for Ascendance. BioTime has a similar Shared Facilities Agreement with Asterias and, as of September 30, 2017, there was a net payable to Asterias of $0.1 million. As of December 31, 2016, BioTime had a receivable from Asterias of approximately $0.3 million.

BioTime accounts for receivables from affiliates, net of payables to affiliates, if any, for similar shared services and other transactions BioTime's consolidated subsidiaries may enter into with nonconsolidated affiliates. BioTime and the affiliates record those receivables and payables on a net basis since BioTime and the affiliate have a legal right of offset of the receivable and the payable, intend to offset those receivables and payables, and settle the balances net by having the party that owes the other party pay the net balance owed.

Other related party transactions

In connection with the capitalization of AgeX as discussed in Note 10, Alfred D. Kingsley, the Chairman of BioTime’s Board of Directors, purchased 200,000 shares of AgeX common stock. The AgeX shares were sold at a price of $2.00 per share pursuant to a series of Stock Purchase Agreements of like tenor.

Mr. Kingsley acquired an additional 421,500 AgeX shares valued at $2.00 per share from BioTime in exchange for 300,000 BioTime common shares owned by Mr. Kingsley valued at $2.81 per share. In connection with its purchase of AgeX shares, BioTime sold 300,000 BioTime common shares to an unaffiliated and existing BioTime investor also for $2.81 per share. The BioTime common shares received from Mr. Kingsley were immediately retired as authorized but unissued shares.

BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost.

Shareholders' Equity

9 Months Ended

Sep. 30, 2017

Shareholders' Equity [Abstract]

Shareholders' Equity

10.	Shareholders' Equity

Preferred Shares

BioTime is authorized to issue 2,000,000 preferred shares. The preferred shares may be issued in one or more series as the board of directors may determine by resolution. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issuance of shares of that series. There are no preferred shares issued and outstanding.

Common Shares

BioTime is authorized to issue 150,000,000 common shares with no par value.

As of September 30, 2017, BioTime had 115,804,040 issued and outstanding common shares and no outstanding treasury stock. As of December 31, 2016, BioTime had 103,396,245 issued and 102,776,539 outstanding common shares. This difference of 619,706 shares between issued and outstanding common shares, as of December 31, 2016, was attributed to the BioTime shares held by OncoCyte which were accounted for as treasury stock on the condensed consolidated balance sheet while OncoCyte was a consolidated subsidiary. Beginning on February 17, 2017, and in connection with the OncoCyte Deconsolidation, those treasury shares are considered to be issued and outstanding BioTime common shares.

During February 2017, BioTime sold 7,453,704 common shares in an underwritten public offering. The offering price to the public was $2.70 per share and net proceeds to BioTime were approximately $18.5 million, after deducting underwriting discounts, commissions and expenses related to the financing.

On April 6, 2017, BioTime, entered into a Controlled Equity Offering^SM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co., as sales agent ("Cantor Fitzgerald"), pursuant to which BioTime may offer and sell, from time to time, through Cantor Fitzgerald, shares of BioTime common stock, no par value per share, having an aggregate offering price of up to $25,000,000. BioTime is not obligated to sell any shares under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, Cantor Fitzgerald will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of the NYSE American, to sell the shares from time to time based upon BioTime's instructions, including any price, time or size limits specified by BioTime. Under the Sales Agreement, Cantor Fitzgerald may sell the shares by any method deemed to be an "at-the-market" offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or by any other method permitted by law, including in privately negotiated transactions. Cantor Fitzgerald's obligations to sell the shares under the Sales Agreement are subject to satisfaction of certain conditions, including the effectiveness of BioTime's Registration Statement on Form S-3 (File No. 333-217182) (the "Registration Statement"), filed with the Securities and Exchange Commission which became effective on May 5, 2017.

BioTime will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cantor Fitzgerald with customary indemnification and contribution rights. The Sales Agreement may be terminated by Cantor Fitzgerald or BioTime at any time upon notice to the other party, or by Cantor Fitzgerald at any time in certain circumstances, including the occurrence of a material and adverse change in BioTime's business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares.

As further disclosed in Note 14, on October 17, 2017, BioTime completed a public offering of 11,057,693 common shares at a price of $2.60 per share, including the underwriters’ full exercise of their over-allotment option to purchase additional shares. The public offering generated net proceeds to BioTime of approximately $26.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by BioTime.

Transactions with Noncontrolling Interests of Cell Cure

BioTime accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary by BioTime under the provisions of ASC 810-10-45-23, Consolidation – Other Presentation Matters, which prescribes the accounting for changes in ownership interest that do not result in a change in control of the subsidiary, as defined by GAAP, before and after the transaction. Under this guidance, changes in a controlling shareholder's ownership interest that do not result in a change of control, as defined by GAAP, in the subsidiary are accounted for as equity transactions. Thus, if the controlling shareholder retains control, no gain or loss is recognized in the statement of operations of the controlling shareholder. Similarly, the controlling shareholder will not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiary if there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and the noncontrolling shareholders occurs based on the respective ownership percentages.

On July 10, 2017, BioTime purchased all of the outstanding Cell Cure Convertible Notes and Cell Cure ordinary shares held by HBL, a Cell Cure shareholder that owned 21.2% of the issued and outstanding Cell Cure ordinary shares and substantially all of the Cell Cure Convertible Notes issued by Cell Cure shareholders other than BioTime (see Note 9). On the same date, BioTime also purchased all of the Cell Cure ordinary shares owned by Teva Pharmaceutical Industries, Ltd. (“Teva”), a former Cell Cure shareholder that owned 16.1% of the issued and outstanding Cell Cure ordinary shares. BioTime issued 2,147,880 common shares valued at $6.6 million based on the closing price of BioTime common shares on the NYSE American to acquire the Cell Cure ordinary shares from HBL and Teva. Prior to the consummation of the transactions with HBL and Teva, BioTime held 62.5% of the issued and outstanding Cell Cure ordinary shares and upon the consummation of the transactions BioTime held 99.8%. In connection with the purchase of the Cell Cure ordinary shares on July 10, 2017, BioTime recorded a $6.6 million charge to equity representing the value of the BioTime common shares on the date of issuance to HBL and Teva, and a $6.6 million proportional equity transfer, at carrying value, from BioTime to Cell Cure recorded in consolidated shareholders' equity representing the purchase of the noncontrolling interests in Cell Cure from HBL and Teva in accordance with ASC 810-10-45-23.

On July 10, 2017, as an inducement to HBL to sell their Cell Cure ordinary shares to BioTime, Cell Cure issued 24,566 warrants to HBL (the “HBL Warrants”) to purchase Cell Cure ordinary shares at an exercise price of $40.5359 per warrant share, payable in U.S. dollars, the same Cell Cure price per ordinary share paid by BioTime to each of HBL and Teva for the purchase of their Cell Cure ordinary shares as discussed above. No warrants were issued to Teva. The HBL Warrants are immediately exercisable and expire on the earliest of the lapse of 5 years from the issuance date or immediately prior to the closing of a Corporate Transaction or an initial public offering, as defined in the HBL Warrant Agreements. Since the exercise price is U.S. dollar-denominated and settlement is not expected to occur in the next twelve months, Cell Cure classified the HBL Warrant as a long-term liability in accordance with ASC 815, Derivatives and Hedging. ASC 815 requires freestanding financial instruments, such as warrants, with exercise prices denominated in currencies other than the functional currency of the issuer to be accounted for as liabilities at fair value, with all subsequent changes in fair value after the issuance date to be recorded in the statements of operations. For the three and nine months ended September 30, 2017, Cell Cure recorded a noncash expense of $531,000 included in general and administrative expenses. As of September 30, 2017, the HBL Warrants, valued at $531,000 were included in other long-term liabilities on the consolidated balance sheet.

See Note 9 for the accounting of the purchase of the Cell Cure Convertible Notes from HBL.

Transactions with Noncontrolling Interests of AgeX Therapeutics, Inc.

In January 2017, AgeX Therapeutics, Inc. was formed by BioTime, which at the time had no operations, assets or liabilities. AgeX was formed to develop BioTime technology relating to cell immortality and regenerative biology by developing products for the treatment of aging and age-related diseases. Initial product development plans include: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are type II diabetes, cardiac ischemia, and cancer, respectively.

On August 17, 2017, AgeX received its initial assets and cash from BioTime and certain outside investors. BioTime contributed certain assets and cash to AgeX in exchange for 28,800,000 shares of AgeX common stock pursuant to an Asset Contribution and Separation Agreement (the “Asset Contribution Agreement”). BioTime and AgeX also entered into a License Agreement pursuant to which BioTime licensed or sublicensed to AgeX, and AgeX granted to BioTime an option to license back, certain patent rights. Concurrently with the acquisition of assets from BioTime under the Asset Contribution Agreement, AgeX sold 4,950,000 shares of its common stock for $10.0 million in cash primarily to outside investors, which included the Chairman of BioTime’s Board of Directors (see Note 9). At the close of the financing, BioTime owned approximately 85% of the issued and outstanding shares of AgeX common stock.

The AgeX shares were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D and Regulation S thereunder. AgeX has agreed to use commercially reasonable efforts to register the shares of AgeX common stock issued to the AgeX investors for sale under the Securities Act.

Asset Contribution Agreement

Assets Contributed:

Pursuant to the Asset Contribution Agreement, BioTime contributed to AgeX the following assets:

Intellectual property and proprietary technology, including certain patents and patent applications and know-how that comprised BioTime’s “iTR” and adipose brown fat tissue technology;

Approximately 95% of the outstanding shares of ReCyte Therapeutics, Inc. (“ReCyte”) common stock, which constituted all of the shares BioTime held prior to the contribution;

Approximately 82% of the outstanding shares of LifeMap Sciences, Inc. (“LifeMap Sciences”) common stock, which constituted all of the shares BioTime held prior to the contribution;

Approximately 44% of the outstanding shares of Ascendance Biotechnology, Inc., (“Ascendance”) which constituted all of the shares BioTime held prior to the contribution.

$100,000 in cash; and

Certain other assets and contracts related to the AgeX research and development programs.

Assumption of Liabilities:

AgeX will assume all third-party obligations and liabilities related to the assets contributed and contracts assigned to AgeX or the operation of the AgeX related business.

Other Matters:

The Asset Contribution Agreement also sets forth other terms that govern certain aspects of BioTime’s ongoing relationship with AgeX if in the future BioTime determines to distribute its AgeX shares to BioTime shareholders.

License Agreement

Concurrently with the contribution of assets to AgeX under the Asset Contribution Agreement, BioTime and AgeX entered into a License Agreement pursuant to which BioTime has licensed to AgeX, with rights to sublicense, certain intellectual property, including patents and patent applications and know-how for use in the development, manufacture and commercialization of products or services for the prevention, treatment, amelioration, diagnosis or monitoring of all human and non-human animal diseases and conditions except for the field of medical products, devices and services for the reserved BioTime fields of orthopedic, ophthalmic and medical aesthetic uses. In addition, BioTime retained an option right to license, on terms to be negotiated, iTR patents in research, development, manufacturing and commercialization of treatments in the reserved BioTime fields. The licensed patents and know-how relate generally to (a) BioTime’s PureStem^® human embryonic progenitor cell lines, and (b) telomere length and DNA quality control analysis in pluripotent stem cells.

The BioTime patent rights licensed to AgeX are exclusive and worldwide except for existing third-party licenses, and for medical products, devices, and services related to tendon. AgeX additionally received an option to license certain BioTime retained patent rights outside of orthopedic indications unless a license grant would compete with a BioTime program or products in the retained BioTime field.

The Asset Contribution Agreement transactions were completed between entities under common control and the assets contributed by BioTime to AgeX were transferred at historical carrying values with no gain or loss recognized in accordance with ASC 810-10-45-23. As a result, pursuant to the new cash investment made by the outside noncontrolling interests in AgeX, this transaction resulted in a $8.2 million proportional equity transfer, at carrying value, from noncontrolling interests in AgeX to BioTime recorded in consolidated shareholders' equity as of September 30, 2017.

Transactions with Noncontrolling Interests of LifeMap Sciences Inc. and LifeMap Solutions Inc.

On June 6, 2017, BioTime increased its ownership in LifeMap Sciences from 78% to 82% and obtained a direct 100% ownership interest in LifeMap Solutions, of which 78% was previously indirectly owned by BioTime through LifeMap Sciences, for settlement and cancellation of certain intercompany debt owed by LifeMap Sciences. This transaction resulted in a $3.1 million equity transfer, at carrying value, between BioTime, LifeMap Sciences and LifeMap Solutions recorded in shareholders' equity as of June 30, 2017, in accordance with the guidance under ASC 810-10-45-23.

Stock Option Plans

9 Months Ended

Sep. 30, 2017

Stock Option Plans [Abstract]

Stock Option Plans

11.	Stock Option Plans

BioTime adopted the 2012 Equity Incentive Plan, as amended (the "2012 Plan"), under which a maximum of 16,000,000 BioTime common shares are available for the grant of stock options, restricted stock, restricted stock units and stock appreciation rights.

A summary of BioTime's 2012 Plan activity and related information follows (in thousands, except per share amounts):

	Shares Available for Grant			Number of Options Outstanding			Number of RSUs Outstanding			Weighted Average Exercise Price of Options
December 31, 2016		2,894			6,958			100		$	3.60
Increase to the 2012 Plan option pool		6,000			-			-			-
Options granted		(1,762	)		1,762			-			3.11
Options exercised		-			(9	)		-			2.66
Restricted stock units vested		-			-			(31	)		-
Options forfeited/cancelled		426			(606	)		-			3.99
September 30, 2017 ⁽¹⁾		7,558			8,105			69		$	3.47
Options exercisable at September 30, 2017					4,072					$	3.71

⁽¹⁾ On October 13, 2017, BioTime’s Board of Directors (the “Board”) determined to temporarily set a limit on shares available for grants of share-based awards pursuant to the 2012 Plan. While that limit remains in place, BioTime will not grant share-based awards for more than a total of approximately 2.5 million of the common shares remaining available for awards under the 2012 Plan.

Stock-Based Compensation Expense

The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions in the following table:

	Nine Months Ended September 30,
	2017			2016
Expected life (in years)		5.47			4.97
Risk-free interest rates		1.78	%		1.43	%
Volatility		59.04	%		60.77	%
Dividend yield		-	%		-	%

Operating expenses include stock-based compensation expense as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
		2017	2016		2017		2016
Research and development	$	326	$	237	$	822	$	2,022
General and administrative		647		473		2,081		4,281
Total stock-based compensation expense	$	973	$	710	$	2,903	$	6,303

Income Taxes

9 Months Ended

Sep. 30, 2017

Income Taxes [Abstract]

Income Taxes

12.	Income Taxes

The provision for income taxes for interim periods is determined using an estimated annual effective tax rate as prescribed by ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances and changes in valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where BioTime conducts business. ASC 740-270 also states that if an entity is unable to reliably estimate a part of its ordinary income or loss, the income tax provision or benefit applicable to the item that cannot be estimated shall be reported in the interim period in which the item is reported.

For items that BioTime cannot reliably estimate on an annual basis (principally unrealized gains or losses generated on its Asterias and OncoCyte shares due to the changes in the respective stock prices of Asterias and OncoCyte), BioTime uses the actual year to date effective tax rate rather than an estimated annual effective tax rate to determine the tax effect of that item, including the use of all available net operating losses and other credits or deferred tax assets.

In connection with the deconsolidation of Asterias and OncoCyte (see Note 3), although neither deconsolidation was a taxable transaction to BioTime and did not create a current income tax payment obligation to BioTime, the market value of the respective shares BioTime holds creates a deferred tax liability to BioTime based on the closing price of the security, less the tax basis of the security BioTime has in such shares. The deferred tax liability generated by the Asterias and OncoCyte shares that BioTime holds as of September 30, 2017, is a source of future taxable income to BioTime, as prescribed by ASC 740-10-30-17, that will more likely than not result in the realization of its deferred tax assets to the extent of those deferred tax liabilities. This deferred tax liability is determined based on the closing price of those securities as of September 30, 2017. Due to the inherent unpredictability of future prices of these securities, BioTime cannot reliably estimate or project those deferred tax liabilities on an annual basis. Therefore, the deferred tax liability pertaining to Asterias and OncoCyte shares, determined based on the actual closing price on the interim period end date being reported on, and the related impacts to the valuation allowance and deferred tax asset changes, are recorded in the interim period in which they occur.

A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized.

For federal income tax purposes, as a result of the deconsolidation of Asterias and OncoCyte as discussed in Note 3 and the deferred tax liabilities generated from the Asterias and OncoCyte share market values from their respective deconsolidation dates, including the changes to those deferred tax liabilities due to changes in the Asterias and OncoCyte stock price through September 30, 2017, BioTime's deferred tax liabilities exceeded its deferred tax assets by $4.8 million as of September 30, 2017. Accordingly, as of September 30, 2017, for federal income tax purposes, BioTime released its entire valuation allowance and recognized a federal deferred income tax expense of $4.8 million during the three and nine months ended September 30, 2017. For state income tax purposes, BioTime has a full valuation allowance on its state deferred tax assets as of September 30, 2017 and December 31, 2016 and, accordingly, no state tax provision or benefit was recorded for any period presented.

BioTime established a full valuation allowance as of December 31, 2016 and 2015 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. Accordingly, BioTime did not record any provision or benefit for income taxes for the three and nine months ended September 30, 2016.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies [Abstract]

Commitments and Contingencies

13.	Commitments and Contingencies

Alameda Lease

On December 10, 2015, BioTime entered into a lease for approximately 30,795 square feet of rentable space in two buildings located in an office park in Alameda, California (the "New Alameda Lease"). The term of the New Alameda Lease is seven years and BioTime has an option to renew the term for an additional five years. BioTime moved into the facility and the term of the New Alameda Lease commenced effective February 1, 2016.

Base rent under the New Alameda Lease commenced on February 1, 2016 at $64,670 per month, and will increase by approximately 3% annually on every February 1 thereafter during the lease term. The lease payments allocated to the landlord liability are amortized as debt service on that liability over the lease term.

Litigation – General

BioTime will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When BioTime is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, BioTime will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, BioTime discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. BioTime is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.

Employment Contracts

BioTime has entered into employment agreements with certain executive officers. Under the provisions of the agreements, BioTime may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations.

Indemnification

In the normal course of business, BioTime may provide indemnifications of varying scope under BioTime's agreements with other companies or consultants, typically BioTime's clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, BioTime will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of BioTime's products and services. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to BioTime products and services. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments BioTime could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, BioTime has not been subject to any claims or demands for indemnification. BioTime also maintains various liability insurance policies that limit BioTime's financial exposure. As a result, BioTime believes the fair value of these indemnification agreements is minimal. Accordingly, BioTime has not recorded any liabilities for these agreements as of September 30, 2017 and December 31, 2016.

Second Amended and Restated License Agreement

On June 15, 2017, Cell Cure entered into a Second Amended and Restated License Agreement (the "License Agreement") with Hadasit Medical Research Services and Development Ltd. ("Hadasit"), the commercial arm and a wholly-owned subsidiary of Hadassah Medical Organization. Pursuant to the License Agreement, Hadasit granted Cell Cure an exclusive, worldwide, royalty bearing license (with the right to grant sublicenses) in its intellectual property portfolio of materials and technology related to human stem cell derived photoreceptor cells and retinal pigment epithelial cells (the "Licensed IP"), to use, commercialize and exploit any part thereof, in any manner whatsoever in the fields of the development and exploitation of (i) human stem cell derived photoreceptor cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders, and (ii) human stem cell derived retinal pigment epithelial cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders.

As consideration for the Licensed IP, Cell Cure will pay a small one-time lump sum payment, a royalty in the mid single digits of net sales from sales of Licensed IP by any invoicing entity, and a royalty of between 15 and 25 percent of sublicensing receipts. In addition, Cell Cure will pay Hadasit an annual minimal non-refundable royalty, which will become due and payable the first January 1 following the completion of services to Cell Cure by a research laboratory.

Cell Cure agreed to pay Hadasit non-refundable milestone payments upon the recruitment of the first patient for the first Phase IIB clinical trial, upon the enrollment of the first patient in the first Phase III clinical trials, upon delivery of the report for the first Phase III clinical trials, upon the receipt of an NDA or marketing approval in the European Union, whichever is the first to occur, and upon the first commercial sale in the United States or European Union, whichever is the first to occur. Such milestones, in the aggregate, may be up to $3.5 million. As of September 30, 2017, Cell Cure had not accrued any milestone payments under the License Agreement.

The License Agreement terminates upon the expiration of Cell Cure's obligation to pay royalties for all licensed products, unless earlier terminated. In addition, the License Agreement may be terminated by (i) Hadasit if, among other reasons, Cell Cure fails to continue the clinical development of the Licensed IP or fails to take actions to commercialize or sell the Licensed IP over any consecutive 12 month period, and (ii) by either party for (a) a material breach which remains uncured following a cure period, or (b) the granting of a winding-up order in respect of the other party, or upon an order being granted against the other party for the appointment of a receiver or a liquidator in respect of a substantial portion of such other party's assets. The License Agreement also contains mutual confidentiality obligations of Cell Cure and Hadasit, and indemnification obligations of Cell Cure.

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

14.	Subsequent Events

On October 17, 2017, BioTime completed a public offering of 11,057,693 common shares at a price of $2.60 per share, including the underwriters’ full exercise of their over-allotment option to purchase additional shares. The public offering generated net proceeds to BioTime of approximately $26.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by BioTime.

BioTime’s existing significant shareholder, Broadwood Partners, L.P., purchased 2,692,307 common shares of in the offering at the public offering price of $2.60 per share. Broadwood Partners, L.P. is affiliated with Neal Bradsher, a member of BioTime’s Board and President of Broadwood Capital, Inc., the general partner of Broadwood Partners, L.P.

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies [Abstract]

Basis of presentation

Principles of consolidation

As of December 31, 2016, OncoCyte's assets, liabilities and net assets are included in the consolidated balance sheet of BioTime, after intercompany eliminations.

Liquidity

Equity method accounting for Asterias and OncoCyte, at fair value

Foreign currency transaction gains and losses

Basic and diluted net income (loss) per share attributable to common shareholders

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Stock options		7,915		5,652		7,871		5,652
Warrants		9,395		9,395		9,395		9,395

Reclassifications

Recently Issued Accounting Pronouncements

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies [Abstract]

Antidilutive securities excluded from computation of earnings per share

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Stock options		7,915		5,652		7,871		5,652
Warrants		9,395		9,395		9,395		9,395

Equity Method Accounting for Common Stock of OncoCyte, at fair value (Tables)

9 Months Ended

Sep. 30, 2017

OncoCyte [Member]

Schedule of Equity Method Investments [Line Items]

Unaudited results of operations

	Three Months Ended September 30,						Nine Months Ended September 30,						For the Period January 1, 2017 to February 16, 2017
	2017			2016			2017			2016
Condensed Statements of Operations (unaudited) ⁽¹⁾:
Research and development expense	$	1,836		$	1,363		$	5,667		$	4,246		$	798
General and administrative expense		4,289			1,063			7,447			3,145			377
Sales and marketing expense		710			156			1,843			655			213
Loss from operations		(6,835	)		(2,582	)		(14,957	)		(8,046	)		(1,388	)
Net loss	$	(6,906	)	$	(2,595	)	$	(15,415	)	$	(8,065	)	$	(1,392	)

Equity Method Accounting for Common Stock of Asterias, at fair value (Tables)

9 Months Ended

Sep. 30, 2017

Asterias Biotherapeutics [Member]

Schedule of Equity Method Investments [Line Items]

Unaudited results of operations

	Three Months Ended September 30,						Nine Months Ended September 30,						For the Period January 1, 2016 to May 12, 2016
	2017			2016			2017			2016
Condensed Statements of Operations (unaudited) ^(1):
Total revenue	$	1,688		$	2,076		$	4,014		$	5,202		$	2,354
Gross profit		1,607			2,017			3,863			5,084			2,301
Loss from operations		(7,063	)		(7,425	)		(24,703	)		(25,591	)		(13,944	)
Net loss	$	(6,809	)	$	(10,648	)	$	(21,824	)	$	(26,144	)	$	(13,113	)

Property, plant and equipment, net (Tables)

9 Months Ended

Sep. 30, 2017

Property, plant and equipment, net [Abstract]

Property, plant and equipment, net

At September 30, 2017 and December 31, 2016, property, plant and equipment was comprised of the following (in thousands):

	September 30, 2017 (unaudited)⁽¹⁾			December 31, 2016
Equipment, furniture and fixtures	$	4,085		$	4,718
Leasehold improvements		4,207			3,791
Accumulated depreciation and amortization		(2,869	)		(2,980	)
Property, plant and equipment, net	$	5,423		$	5,529

⁽¹⁾ Reflects the effect of the OncoCyte Deconsolidation.

Intangible assets, net (Tables)

9 Months Ended

Sep. 30, 2017

Intangible assets, net [Abstract]

Intangible assets

At September 30, 2017 and December 31, 2016, intangible assets, primarily consisting of acquired patents, and accumulated amortization were as follows (in thousands):

	September 30, 2017 (unaudited)⁽¹⁾			December 31, 2016
Intangible assets	$	23,294		$	25,703
Accumulated amortization		(15,812	)		(15,497	)
Intangible assets, net	$	7,482		$	10,206

⁽¹⁾ Reflects the effect of the OncoCyte Deconsolidation.

Accounts Payable and Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2017

Accounts Payable and Accrued Liabilities [Abstract]

Accounts payable and accrued liabilities

At September 30, 2017 and December 31, 2016, accounts payable and accrued liabilities consisted of the following (in thousands):

	September 30, 2017 (unaudited)⁽¹⁾		December 31, 2016
Accounts payable	$	508	$	1,593
Accrued expenses		2,775		3,212
Accrued compensation		1,782		1,904
Other current liabilities		295		435
Total	$	5,360	$	7,144

⁽¹⁾ Reflects the effect of the OncoCyte Deconsolidation.

Stock Option Plans (Tables)

9 Months Ended

Sep. 30, 2017

Stock Option Plans [Abstract]

Summary of stock option activity

A summary of BioTime's 2012 Plan activity and related information follows (in thousands, except per share amounts):

	Shares Available for Grant			Number of Options Outstanding			Number of RSUs Outstanding			Weighted Average Exercise Price of Options
December 31, 2016		2,894			6,958			100		$	3.60
Increase to the 2012 Plan option pool		6,000			-			-			-
Options granted		(1,762	)		1,762			-			3.11
Options exercised		-			(9	)		-			2.66
Restricted stock units vested		-			-			(31	)		-
Options forfeited/cancelled		426			(606	)		-			3.99
September 30, 2017 ⁽¹⁾		7,558			8,105			69		$	3.47
Options exercisable at September 30, 2017					4,072					$	3.71

Schedule of weighted average assumptions to calculate fair value of stock options

The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions in the following table:

	Nine Months Ended September 30,
	2017			2016
Expected life (in years)		5.47			4.97
Risk-free interest rates		1.78	%		1.43	%
Volatility		59.04	%		60.77	%
Dividend yield		-	%		-	%

Schedule of stock based compensation expense

Operating expenses include stock-based compensation expense as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
		2017	2016		2017		2016
Research and development	$	326	$	237	$	822	$	2,022
General and administrative		647		473		2,081		4,281
Total stock-based compensation expense	$	973	$	710	$	2,903	$	6,303

Organization and Business Overview (Details) $ in Thousands		9 Months Ended
Organization and Business Overview (Details) $ in Thousands	Aug. 17, 2017 USD ($)	Sep. 30, 2017 USD ($) Sector Technology Subsidiary Program	Sep. 30, 2016 USD ($)
Organization and Business Overview [Abstract]
Number of primary sectors \| Sector		3
Number of platform technologies \| Technology		2
Number of subsidiaries \| Subsidiary		2
Number of clinical stage programs \| Program		3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from sale of common shares of subsidiary		$ 9,968	$ 0
AgeX Therapeutics, Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from sale of common shares of subsidiary	$ 10,000
Ownership percentage	85.00%

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Details) $ in Thousands, ₪ in Millions						3 Months Ended			6 Months Ended	9 Months Ended
	Oct. 17, 2017 USD ($)	Sep. 18, 2017 USD ($)	Aug. 17, 2017 USD ($)	Aug. 08, 2017 USD ($)	Aug. 08, 2017 ILS (₪)	Sep. 30, 2017 USD ($) shares	Jun. 30, 2017 USD ($)	Sep. 30, 2016 USD ($) shares	Jun. 30, 2017 USD ($)	Sep. 30, 2017 USD ($) shares	Sep. 30, 2016 USD ($) shares	Dec. 31, 2016 USD ($)
Liquidity [Abstract]
Accumulated deficit						$ 144,363				$ 144,363		$ 196,321
Shareholders' equity						198,286				198,286		$ 117,928
Proceeds from sale of common shares of subsidiary										9,968	$ 0
Grants approved						$ 1,225		$ 1,109		$ 1,236	$ 3,346
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) \| shares						115,298		103,613		111,124	99,073
Reclassification [Abstract]
Gain on sale of assets						$ 0	$ 1,800	$ 0	$ 1,800	$ 1,754	$ 0
IIA (formerly OCS) grant income (Cell Cure, Israel) [Member]
Liquidity [Abstract]
Grants approved				$ 2,000
Grants receivable						1,200				1,200
IIA (formerly OCS) grant income (Cell Cure, Israel) [Member] \| Maximum [Member]
Liquidity [Abstract]
Grants approved \| ₪					₪ 7.2
N I H Grant Income [Member] \| Maximum [Member]
Liquidity [Abstract]
Grants approved		$ 1,560
Asterias Biotherapeutics and OncoCyte [Member]
Liquidity [Abstract]
Cash and cash equivalents, available for sale securities, combined value						184,700				184,700
AgeX [Member]
Liquidity [Abstract]
Proceeds from sale of common shares of subsidiary			$ 10,000
Parent [Member]
Liquidity [Abstract]
Accumulated deficit						(144,400)				(144,400)
Working capital						17,200				17,200
Shareholders' equity						209,000				209,000
Cash, cash equivalents and available for sale securities						$ 18,200				$ 18,200
Parent [Member] \| Subsequent Event [Member]
Liquidity [Abstract]
Net proceeds from underwritten public offering	$ 26,700
Treasury Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) \| shares								620,000		109,000	3,400,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) \| shares						10,000		282,000		26,000	154,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares) \| shares						10,000		282,000		26,000	154,000
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares) \| shares						7,915,000		5,652,000		7,871,000	5,652,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares) \| shares						9,395,000		9,395,000		9,395,000	9,395,000

Deconsolidation of OncoCyte and Asterias (Details) - OncoCyte [Member] - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Feb. 17, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Noncontrolling Interest [Line Items]
Issuance of common stock to certain investors upon exercise of warrants (in shares)	625,000
Gain on deconsolidation		$ 0	$ 0	$ 71,697	$ 0
Maximum [Member]
Noncontrolling Interest [Line Items]
Equity method ownership percentage	50.00%

Equity Method Accounting for Common Stock of OncoCyte, at fair value (Details) - OncoCyte [Member] - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions

2 Months Ended

3 Months Ended

9 Months Ended

Feb. 16, 2017

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Jun. 30, 2017

Feb. 17, 2017

Schedule of Equity Method Investments [Line Items]

Common stock, outstanding (in shares)

14.7

Fair value on investment

$ 110,800

$ 71,200

Price per share on NYSE American (in dollars per share)

$ 7.55

$ 5.20

$ 4.85

Unrealized gains on equity method investment

$ 34,500

$ 39,600

Condensed Statements of Operations (unaudited) [Abstract]

Research and development expense

^[1]

$ 798

1,836

$ 1,363

5,667

$ 4,246

General and administrative expense

^[1]

377

4,289

1,063

7,447

3,145

Sales and marketing expense

^[1]

213

710

156

1,843

655

Loss from operations

^[1]

(1,388)

(6,835)

(2,582)

(14,957)

(8,046)

Net loss

^[1]

$ (1,392)

$ (6,906)

$ (2,595)

$ (15,415)

$ (8,065)

[1]

The condensed unaudited statements of operations information included in the table above for the period January 1, 2017 through February 16, 2017, and for the three and nine months ended September 30, 2016, reflects OncoCyte results of operations included in BioTime's condensed consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016, as applicable, respectively, after intercompany eliminations. The information for OncoCyte for the period from February 17, 2017 through September 30, 2017 is not included in BioTime's condensed consolidated statements of operations for the three and nine months ended September 30, 2017, due to the OncoCyte Deconsolidation on February 17, 2017.

Equity Method Accounting for Common Stock of Asterias, at fair value (Details) - Asterias Biotherapeutics, Inc. [Member] - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions

3 Months Ended

4 Months Ended

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

May 12, 2016

Sep. 30, 2017

Sep. 30, 2016

Jun. 30, 2017

Dec. 31, 2016

May 13, 2016

Schedule of Equity Method Investments [Line Items]

Common stock, outstanding (in shares)

21.7

Fair value on investment

$ 73,900

$ 100,000

Price per share on NYSE American (in dollars per share)

$ 3.40

$ 3.55

$ 4.60

Unrealized (loss) on equity method investment

$ (3,300)

$ (26,100)

Condensed Statements of Operations (unaudited) [Abstract]

Total revenue

^[1]

1,688

$ 2,076

$ 2,354

4,014

$ 5,202

Gross profit

^[1]

1,607

2,017

2,301

3,863

5,084

Loss from operations

^[1]

(7,063)

(7,425)

(13,944)

(24,703)

(25,591)

Net loss

^[1]

$ (6,809)

$ (10,648)

$ (13,113)

$ (21,824)

$ (26,144)

[1]

The condensed unaudited statement of operations information included in the table above reflects Asterias' results of operations for the three and nine months ended September 30, 2017 and 2016. The periods shown are provided for comparative purposes only, and the condensed results of operations of Asterias shown for the three and nine months ended September 30, 2017 were not included in BioTime's condensed consolidated statements of operations. The unaudited results of operations of Asterias for the period January 1, 2016 through May 12, 2016 only are included in the unaudited condensed consolidated results of BioTime for the nine months ended September 30, 2016 due to the Asterias Deconsolidation on May 13, 2016.

Property, plant and equipment, net (Details) - USD ($)
$ in Thousands

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Dec. 31, 2016

Property, plant and equipment net [Abstract]

Accumulated depreciation and amortization

$ (2,869)

^[1]

$ (2,980)

Property, plant and equipment, net

5,423

^[1]

5,529

Depreciation and amortization expense

670

$ 996

Equipment, Furniture and Fixtures [Member]

Property, plant and equipment net [Abstract]

Property, plant and equipment

4,085

^[1]

4,718

Leasehold Improvements [Member]

Property, plant and equipment net [Abstract]

Property, plant and equipment

4,207

^[1]

$ 3,791

Depreciation and amortization expense

$ 670

$ 996

[1]	Reflects the effect of the OncoCyte Deconsolidation.

Intangible assets, net (Details) - USD ($)
$ in Thousands

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Dec. 31, 2016

Intangible assets, net [Abstract]

Intangible assets

$ 23,294

^[1]

$ 25,703

Accumulated amortization

(15,812)

^[1]

(15,497)

Intangible assets, net

7,482

^[1]

$ 10,206

Amortization of intangible assets

$ 1,766

$ 2,935

[1]	Reflects the effect of the OncoCyte Deconsolidation.

Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands

Sep. 30, 2017

^[1]

Dec. 31, 2016

Accounts Payable and Accrued Liabilities [Abstract]

Accounts payable

$ 508

$ 1,593

Accrued expenses

2,775

3,212

Accrued compensation

1,782

1,904

Other current liabilities

295

435

Total

$ 5,360

$ 7,144

[1]	Reflects the effect of the OncoCyte Deconsolidation.

Related Party Transactions (Details)				1 Months Ended	3 Months Ended		9 Months Ended
Related Party Transactions (Details)	Oct. 17, 2017 $ / shares shares	Aug. 17, 2017 $ / shares shares	Jul. 10, 2017 USD ($) $ / shares shares	Feb. 28, 2017 $ / shares shares	Sep. 30, 2017 USD ($) ft² $ / shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) ft² $ / shares shares	Sep. 30, 2016 USD ($)	Jun. 30, 2017 $ / shares	Feb. 17, 2017 $ / shares	Dec. 31, 2016 USD ($) $ / shares
Related Party Transaction [Line Items]
Carrying value of convertible notes					$ 0		$ 0				$ 1,032,000
Common stock issued to unaffiliated and existing investors (in shares) \| shares		300,000
Common stock price per share issued to unaffiliated and existing investors (in dollars per share) \| $ / shares		$ 2.81
Loss on debt extinguishment					$ (2,799,000)	$ 0	(2,799,000)	$ 0
Rent per month							$ 5,050
Area of office space (in square feet) \| ft²					900		900
Common Stock [Member]
Related Party Transaction [Line Items]
Common shares issued (in shares) \| shares	11,057,693			7,453,704
Price per share on NYSE MKT (in dollars per share) \| $ / shares			$ 3.09
Stock price per share (in dollars per share) \| $ / shares	$ 2.60			$ 2.70
OncoCyte [Member]
Related Party Transaction [Line Items]
Price per share on NYSE MKT (in dollars per share) \| $ / shares					$ 7.55		$ 7.55		$ 5.20	$ 4.85
Markup rate on allocated costs							5.00%
Interest rate charged on unpaid and overdue invoices							15.00%
Receivables from related party					$ 2,100,000		$ 2,100,000
OncoCyte [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Term of payment							30 days
Asterias Biotherapeutics [Member]
Related Party Transaction [Line Items]
Price per share on NYSE MKT (in dollars per share) \| $ / shares					$ 3.40		$ 3.40		$ 3.55		$ 4.60
Receivables from related party											$ 300,000
Net payables to related party					$ 100,000		$ 100,000
Ascendance Biotechnology, Inc [Member]
Related Party Transaction [Line Items]
Receivables from related party					$ 300,000		$ 300,000
Hadasit Bio-Holdings, Ltd [Member]
Related Party Transaction [Line Items]
Ownership percentage, noncontrolling owners			21.20%
AgeX Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Common shares issued (in shares) \| shares		4,950,000
Alfred D. Kingsley [Member]
Related Party Transaction [Line Items]
Common stock shares converted (in shares) \| shares		300,000
Common stock shares converted price per share (in dollars per shares) \| $ / shares		$ 2.81
Alfred D. Kingsley [Member] \| AgeX Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Common shares issued (in shares) \| shares							200,000
Stock price per share (in dollars per share) \| $ / shares		$ 2.00
Additional common shares purchased (in shares) \| shares		421,500
Additional common stock shares purchased price per share (in dollars per share) \| $ / shares		$ 2.00
Cell Cure Neurosciences, Ltd. [Member]
Related Party Transaction [Line Items]
Carrying value of convertible notes											1,865,000
Amount of accrued interest											2,544,000
Unamortized debt discount											$ 679,000
Cell Cure Neurosciences, Ltd. [Member] \| Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Stated interest rate					3.00%		3.00%
Conversion price (in dollars per share) \| $ / shares					$ 20.00		$ 20.00
Accrued interest is payable period							3 years
Cell Cure Neurosciences, Ltd. [Member] \| Convertible Notes Payable [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Estimated fair market value (in dollars per share) \| $ / shares							$ 28.00
Intrinsic value (in dollars per share) \| $ / shares							$ 8
Effective annual interest rate					11.00%		11.00%
Cell Cure Neurosciences, Ltd. [Member] \| Convertible Notes Payable [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Estimated fair market value (in dollars per share) \| $ / shares							$ 40.00
Intrinsic value (in dollars per share) \| $ / shares							$ 20
Effective annual interest rate					23.00%		23.00%
Cell Cure Neurosciences, Ltd. [Member] \| Hadasit Bio-Holdings, Ltd [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Common shares issued (in shares) \| shares			1,220,207
Common shares issued value			$ 3,800,000
Cell Cure Neurosciences, Ltd. [Member] \| Hadasit Bio-Holdings, Ltd [Member] \| Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Intrinsic value of equity							$ 3,100,000
Loss on debt extinguishment					$ 2,800,000		$ 2,800,000
Cell Cure Neurosciences, Ltd. [Member] \| Hadasit Bio-Holdings, Ltd [Member] \| Convertible Notes Payable [Member] \| Common Stock [Member]
Related Party Transaction [Line Items]
Common shares issued (in shares) \| shares			2,776,662
Common shares issued value			$ 8,600,000

Shareholders' Equity (Details) - USD ($)					1 Months Ended	3 Months Ended	9 Months Ended
Shareholders' Equity (Details) - USD ($)	Oct. 17, 2017	Aug. 17, 2017	Jul. 10, 2017	Jun. 06, 2017	Feb. 28, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Apr. 06, 2017	Dec. 31, 2016
Preferred Shares [Abstract]
Preferred shares, shares authorized (in shares)						2,000,000	2,000,000			2,000,000
Preferred shares, shares issued (in shares)						0	0			0
Preferred shares, shares outstanding (in shares)						0	0			0
Common Shares [Abstract]
Common stock, shares authorized (in shares)						150,000,000	150,000,000			150,000,000
Common stock, par value (in dollars per share)						$ 0	$ 0			$ 0
Common stock, issued (in shares)						115,804,040	115,804,040			103,396,245
Common stock, outstanding (in shares)						115,804,040	115,804,040			102,776,539
Treasury stock (in shares)						0	0			619,706
Noncash expense							$ 2,903,000	$ 6,303,000
Proceeds from sale of common shares of subsidiary							$ 9,968,000	$ 0
Transfer of ownership at carrying value				$ 3,100,000
Common Stock [Member]
Common Shares [Abstract]
Number of shares sold (in shares)	11,057,693				7,453,704
Purchase price per share (in dollars per share)	$ 2.60				$ 2.70
Proceeds from sale of stock	$ 26,700,000				$ 18,500,000
Cell Cure Neurosciences, Ltd. [Member]
Common Shares [Abstract]
Ownership percentage			99.80%			62.50%	62.50%
Cell Cure Neurosciences, Ltd. [Member] \| General and Administrative Expenses [Member]
Common Shares [Abstract]
Noncash expense						$ 531,000	$ 531,000
Cell Cure Neurosciences, Ltd. [Member] \| Common Stock [Member]
Common Shares [Abstract]
Number of shares sold (in shares)			2,147,880
Common shares issued value			$ 6,600,000
LifeMap Sciences, Inc. [Member]
Common Shares [Abstract]
Ownership percentage				82.00%						78.00%
Percentage of outstanding shares contributed to acquire subsidiary							82.00%
LifeMap Solutions, Inc [Member]
Common Shares [Abstract]
Ownership percentage				100.00%
Hadasit Bio-Holdings, Ltd [Member]
Common Shares [Abstract]
Ownership percentage, noncontrolling owners			21.20%
Warrants issued to purchase ordinary shares (in shares)			24,566
Warrants exercise price (in dollars per share)			$ 40.5359
Warrants exercisable term							5 years
Hadasit Bio-Holdings, Ltd [Member] \| Other Long-Term Liabilities [Member]
Common Shares [Abstract]
Value of warrants						531,000	$ 531,000
Teva Pharmaceutical Industries, Ltd [Member]
Common Shares [Abstract]
Ownership percentage, noncontrolling owners			16.10%
Warrants issued to purchase ordinary shares (in shares)			0
AgeX [Member]
Common Shares [Abstract]
Number of shares sold (in shares)		4,950,000
Ownership percentage		85.00%
Number of shares acquired from subsidiary in terms exchange (in shares)		28,800,000
Proceeds from sale of common shares of subsidiary		$ 10,000,000
Cash contributed to acquire subsidiary							100,000
Carrying value of equity transfer						$ 8,200,000	$ 8,200,000
ReCyte Therapeutics, Inc. [Member]
Common Shares [Abstract]
Percentage of outstanding shares contributed to acquire subsidiary							95.00%
Ascendance Biotechnology, Inc. [Member]
Common Shares [Abstract]
Percentage of outstanding shares contributed to acquire subsidiary							44.00%
Cantor Fitzgerald & Co [Member]
Common Shares [Abstract]
Percentage of commission payable							3.00%
Cantor Fitzgerald & Co [Member] \| Maximum [Member]
Common Shares [Abstract]
Aggregate offering price									$ 25,000,000

Stock Option Plans (Details) - 2012 Plan [Member] - $ / shares

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Oct. 13, 2017

Sep. 30, 2017

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares available for grants (in shares)

2,894,000

7,558,000

^[1]

Shares Available for Grant [Roll Forward]

Beginning of the period (in shares)

2,894,000

Increase to the 2012 Plan option pool (in shares)

6,000,000

Options granted (in shares)

(1,762,000)

Options exercised (in shares)

Options forfeited/cancelled (in shares)

426,000

End of the period (in shares)

^[1]

7,558,000

Number of Options Outstanding [Rollforward]

Outstanding, beginning of the period (in shares)

6,958,000

Increase to the 2012 Plan option pool (in shares)

Options granted (in shares)

1,762,000

Options exercised (in shares)

(9,000)

Options forfeited/cancelled (in shares)

(606,000)

Outstanding, end of the period (in shares)

^[1]

8,105,000

Options exercisable, end of period (in shares)

4,072,000

Number of RSUs Outstanding [Roll Forward]

Outstanding, beginning of the period (in shares)

100,000

Restricted stock units vested (in shares)

(31,000)

Outstanding, end of the period (in shares)

^[1]

69,000

Weighted Average Exercise Price of Options [Rollforward]

Outstanding, beginning of the period (in dollars per share)

$ 3.60

Increase to the 2012 Plan option pool (in dollars per share)

Options granted (in dollars per share)

3.11

Options exercised (in dollars per share)

2.66

Options forfeited/cancelled (in dollars per share)

3.99

Outstanding end of the period (in dollars per share)

^[1]

3.47

Options exercisable, end of period (in dollars per share)

$ 3.71

Weighted-average assumptions [Abstract]

Expected life

5 years 5 months 19 days

4 years 11 months 19 days

Risk-free interest rates

1.78%

1.43%

Volatility

59.04%

60.77%

Dividend yield

0.00%

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common shares reserved for future issuance (in shares)

16,000,000

Maximum [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares available for grants (in shares)

2,500,000

[1]

On October 13, 2017, BioTime's Board of Directors (the "Board") determined to temporarily set a limit on shares available for grants for share-based awards pursuant to the 2012 Plan. While that limit remains in place, BioTime will not grant share-based awards for more than a total of approximately 2.5 million of the common shares remaining available for awards under the 2012 Plan.

Stock Option Plans, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	$ 973	$ 710	$ 2,903	$ 6,303
Research and Development [Member]
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	326	237	822	2,022
General and Administrative [Member]
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	$ 647	$ 473	$ 2,081	$ 4,281

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Deferred tax liabilities, net	$ 4.8	$ 4.8
Deferred income tax expense (benefit), federal	5.2	4.8
Deferred income tax expense (benefit), state taxes		0.0	$ 0.0
Provision for income taxes	$ 0.0	$ 0.0

Commitments and Contingencies (Details)	9 Months Ended
Commitments and Contingencies (Details)	Sep. 30, 2017 USD ($) ft² Building
Cell Cure Neurosciences, Ltd. [Member]
Operating Leased Assets [Line Items]
Accrued milestone payments	$ 0
Cell Cure Neurosciences, Ltd. [Member] \| Minimum [Member]
Operating Leased Assets [Line Items]
Royalty revenue percentage	15.00%
Cell Cure Neurosciences, Ltd. [Member] \| Maximum [Member]
Operating Leased Assets [Line Items]
Royalty revenue percentage	25.00%
Milestone payments	$ 3,500,000
New Alameda Lease [Member]
Operating Leased Assets [Line Items]
Leased area \| ft²	30,795
Number of buildings for lease \| Building	2
Lease term	7 years
Number of years lease can be extended	5 years
Lease commencement date	Feb. 01, 2016
Base rent	$ 64,670
Base rent increase rate	3.00%

Subsequent Events (Details) - Common Stock [Member] - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Oct. 17, 2017	Feb. 28, 2017
Subsequent Event [Line Items]
Common shares issued (in shares)	11,057,693	7,453,704
Stock price per share (in dollars per share)	$ 2.60	$ 2.70
Proceeds from sale of stock	$ 26.7	$ 18.5
Subsequent Event [Member]
Subsequent Event [Line Items]
Common shares issued (in shares)	11,057,693
Stock price per share (in dollars per share)	$ 2.60
Proceeds from sale of stock	$ 26.7
Subsequent Event [Member] \| Broadwood Partners LP [Member]
Subsequent Event [Line Items]
Common shares issued (in shares)	2,692,307
Stock price per share (in dollars per share)	$ 2.60